Cargando…

T cell receptor repertoire characteristics both before and following immunotherapy correlate with clinical response in mesothelioma

BACKGROUND: Malignant pleural mesothelioma (MPM) is a highly lethal malignancy in need for new treatment options. Although immunotherapies have been shown to boost a tumor-specific immune response, not all patients respond and prognostic biomarkers are scarce. In this study, we determined the periph...

Descripción completa

Detalles Bibliográficos
Autores principales: Vroman, Heleen, Balzaretti, Giulia, Belderbos, Robert A, Klarenbeek, Paul L, van Nimwegen, Menno, Bezemer, Koen, Cornelissen, Robin, Niewold, Ilse T G, van Schaik, Barbera D, van Kampen, Antione H, Aerts, Joachim G J V, de Vries, Niek, Hendriks, Rudi W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7174074/
https://www.ncbi.nlm.nih.gov/pubmed/32234848
http://dx.doi.org/10.1136/jitc-2019-000251
_version_ 1783524563415465984
author Vroman, Heleen
Balzaretti, Giulia
Belderbos, Robert A
Klarenbeek, Paul L
van Nimwegen, Menno
Bezemer, Koen
Cornelissen, Robin
Niewold, Ilse T G
van Schaik, Barbera D
van Kampen, Antione H
Aerts, Joachim G J V
de Vries, Niek
Hendriks, Rudi W
author_facet Vroman, Heleen
Balzaretti, Giulia
Belderbos, Robert A
Klarenbeek, Paul L
van Nimwegen, Menno
Bezemer, Koen
Cornelissen, Robin
Niewold, Ilse T G
van Schaik, Barbera D
van Kampen, Antione H
Aerts, Joachim G J V
de Vries, Niek
Hendriks, Rudi W
author_sort Vroman, Heleen
collection PubMed
description BACKGROUND: Malignant pleural mesothelioma (MPM) is a highly lethal malignancy in need for new treatment options. Although immunotherapies have been shown to boost a tumor-specific immune response, not all patients respond and prognostic biomarkers are scarce. In this study, we determined the peripheral blood T cell receptor β (TCRβ) chain repertoire of nine MPM patients before and 5 weeks after the start of dendritic cell (DC)-based immunotherapy. MATERIALS AND METHODS: We separately profiled PD1(+) and PD1(−)CD4(+) and CD8(+) T cells, as well as Tregs and analyzed 70 000 TCRβ sequences per patient. RESULTS: Strikingly, limited TCRβ repertoire diversity and high average clone sizes in total CD3(+) T cells before the start of immunotherapy were associated with a better clinical response. To explore the differences in TCRβ repertoire prior-DC-therapy and post-DC-therapy, for each patient the TCRβ clones present in the total CD3(+) T cell fractions were classified into five categories, based on therapy-associated frequency changes: expanding, decreasing, stable, newly appearing and disappearing clones. Subsequently, the presence of these five groups of clones was analyzed in the individual sorted T cell fractions. DC-therapy primarily induced TCRβ repertoire changes in the PD1(+)CD4(+) and PD1(+)CD8(+) T cell fractions. In particular, in the PD1(+)CD8(+) T cell subpopulation we found high frequencies of expanding, decreasing and newly appearing clones. Conversion from a PD1(−) to a PD1(+) phenotype was significantly more frequent in CD8(+) T cells than in CD4(+) T cells. Hereby, the number of expanding PD1(+)CD8(+) T cell clones—and not expanding PD1(+)CD4(+) T cell clones following immunotherapy positively correlated with overall survival, progression-free survival and reduction of tumor volume. CONCLUSION: We conclude that the clinical response to DC-mediated immunotherapy is dependent on both the pre-existing TCRβ repertoire of total CD3(+) T cells and on therapy-induced changes, in particular expanding PD1(+)CD8(+) T cell clones. Therefore, TCRβ repertoire profiling in sorted T cell subsets could serve as predictive biomarker for the selection of MPM patients that benefit from immunotherapy. TRIAL REGISTRATION NUMBER: NCT02395679.
format Online
Article
Text
id pubmed-7174074
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-71740742020-04-27 T cell receptor repertoire characteristics both before and following immunotherapy correlate with clinical response in mesothelioma Vroman, Heleen Balzaretti, Giulia Belderbos, Robert A Klarenbeek, Paul L van Nimwegen, Menno Bezemer, Koen Cornelissen, Robin Niewold, Ilse T G van Schaik, Barbera D van Kampen, Antione H Aerts, Joachim G J V de Vries, Niek Hendriks, Rudi W J Immunother Cancer Short Report BACKGROUND: Malignant pleural mesothelioma (MPM) is a highly lethal malignancy in need for new treatment options. Although immunotherapies have been shown to boost a tumor-specific immune response, not all patients respond and prognostic biomarkers are scarce. In this study, we determined the peripheral blood T cell receptor β (TCRβ) chain repertoire of nine MPM patients before and 5 weeks after the start of dendritic cell (DC)-based immunotherapy. MATERIALS AND METHODS: We separately profiled PD1(+) and PD1(−)CD4(+) and CD8(+) T cells, as well as Tregs and analyzed 70 000 TCRβ sequences per patient. RESULTS: Strikingly, limited TCRβ repertoire diversity and high average clone sizes in total CD3(+) T cells before the start of immunotherapy were associated with a better clinical response. To explore the differences in TCRβ repertoire prior-DC-therapy and post-DC-therapy, for each patient the TCRβ clones present in the total CD3(+) T cell fractions were classified into five categories, based on therapy-associated frequency changes: expanding, decreasing, stable, newly appearing and disappearing clones. Subsequently, the presence of these five groups of clones was analyzed in the individual sorted T cell fractions. DC-therapy primarily induced TCRβ repertoire changes in the PD1(+)CD4(+) and PD1(+)CD8(+) T cell fractions. In particular, in the PD1(+)CD8(+) T cell subpopulation we found high frequencies of expanding, decreasing and newly appearing clones. Conversion from a PD1(−) to a PD1(+) phenotype was significantly more frequent in CD8(+) T cells than in CD4(+) T cells. Hereby, the number of expanding PD1(+)CD8(+) T cell clones—and not expanding PD1(+)CD4(+) T cell clones following immunotherapy positively correlated with overall survival, progression-free survival and reduction of tumor volume. CONCLUSION: We conclude that the clinical response to DC-mediated immunotherapy is dependent on both the pre-existing TCRβ repertoire of total CD3(+) T cells and on therapy-induced changes, in particular expanding PD1(+)CD8(+) T cell clones. Therefore, TCRβ repertoire profiling in sorted T cell subsets could serve as predictive biomarker for the selection of MPM patients that benefit from immunotherapy. TRIAL REGISTRATION NUMBER: NCT02395679. BMJ Publishing Group 2020-03-30 /pmc/articles/PMC7174074/ /pubmed/32234848 http://dx.doi.org/10.1136/jitc-2019-000251 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Short Report
Vroman, Heleen
Balzaretti, Giulia
Belderbos, Robert A
Klarenbeek, Paul L
van Nimwegen, Menno
Bezemer, Koen
Cornelissen, Robin
Niewold, Ilse T G
van Schaik, Barbera D
van Kampen, Antione H
Aerts, Joachim G J V
de Vries, Niek
Hendriks, Rudi W
T cell receptor repertoire characteristics both before and following immunotherapy correlate with clinical response in mesothelioma
title T cell receptor repertoire characteristics both before and following immunotherapy correlate with clinical response in mesothelioma
title_full T cell receptor repertoire characteristics both before and following immunotherapy correlate with clinical response in mesothelioma
title_fullStr T cell receptor repertoire characteristics both before and following immunotherapy correlate with clinical response in mesothelioma
title_full_unstemmed T cell receptor repertoire characteristics both before and following immunotherapy correlate with clinical response in mesothelioma
title_short T cell receptor repertoire characteristics both before and following immunotherapy correlate with clinical response in mesothelioma
title_sort t cell receptor repertoire characteristics both before and following immunotherapy correlate with clinical response in mesothelioma
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7174074/
https://www.ncbi.nlm.nih.gov/pubmed/32234848
http://dx.doi.org/10.1136/jitc-2019-000251
work_keys_str_mv AT vromanheleen tcellreceptorrepertoirecharacteristicsbothbeforeandfollowingimmunotherapycorrelatewithclinicalresponseinmesothelioma
AT balzarettigiulia tcellreceptorrepertoirecharacteristicsbothbeforeandfollowingimmunotherapycorrelatewithclinicalresponseinmesothelioma
AT belderbosroberta tcellreceptorrepertoirecharacteristicsbothbeforeandfollowingimmunotherapycorrelatewithclinicalresponseinmesothelioma
AT klarenbeekpaull tcellreceptorrepertoirecharacteristicsbothbeforeandfollowingimmunotherapycorrelatewithclinicalresponseinmesothelioma
AT vannimwegenmenno tcellreceptorrepertoirecharacteristicsbothbeforeandfollowingimmunotherapycorrelatewithclinicalresponseinmesothelioma
AT bezemerkoen tcellreceptorrepertoirecharacteristicsbothbeforeandfollowingimmunotherapycorrelatewithclinicalresponseinmesothelioma
AT cornelissenrobin tcellreceptorrepertoirecharacteristicsbothbeforeandfollowingimmunotherapycorrelatewithclinicalresponseinmesothelioma
AT niewoldilsetg tcellreceptorrepertoirecharacteristicsbothbeforeandfollowingimmunotherapycorrelatewithclinicalresponseinmesothelioma
AT vanschaikbarberad tcellreceptorrepertoirecharacteristicsbothbeforeandfollowingimmunotherapycorrelatewithclinicalresponseinmesothelioma
AT vankampenantioneh tcellreceptorrepertoirecharacteristicsbothbeforeandfollowingimmunotherapycorrelatewithclinicalresponseinmesothelioma
AT aertsjoachimgjv tcellreceptorrepertoirecharacteristicsbothbeforeandfollowingimmunotherapycorrelatewithclinicalresponseinmesothelioma
AT devriesniek tcellreceptorrepertoirecharacteristicsbothbeforeandfollowingimmunotherapycorrelatewithclinicalresponseinmesothelioma
AT hendriksrudiw tcellreceptorrepertoirecharacteristicsbothbeforeandfollowingimmunotherapycorrelatewithclinicalresponseinmesothelioma